- Home
- BMEA vs LPSN Comparison
BMEA vs LPSN Comparison
Compare BMEA & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- LPSN
- Stock Information
- Founded
- BMEA 2017
- LPSN 1995
- Country
- BMEA United States
- LPSN United States
- Employees
- BMEA N/A
- LPSN N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- LPSN EDP Services
- Sector
- BMEA Health Care
- LPSN Technology
- Exchange
- BMEA Nasdaq
- LPSN Nasdaq
- Market Cap
- BMEA 103.5M
- LPSN 97.6M
- IPO Year
- BMEA 2021
- LPSN 2000
- Fundamental
- Price
- BMEA $1.83
- LPSN $1.11
- Analyst Decision
- BMEA Strong Buy
- LPSN Hold
- Analyst Count
- BMEA 10
- LPSN 1
- Target Price
- BMEA $17.70
- LPSN N/A
- AVG Volume (30 Days)
- BMEA 683.1K
- LPSN 8.2M
- Earning Date
- BMEA 08-05-2025
- LPSN 08-11-2025
- Dividend Yield
- BMEA N/A
- LPSN N/A
- EPS Growth
- BMEA N/A
- LPSN N/A
- EPS
- BMEA N/A
- LPSN N/A
- Revenue
- BMEA N/A
- LPSN $271,750,000.00
- Revenue This Year
- BMEA N/A
- LPSN N/A
- Revenue Next Year
- BMEA N/A
- LPSN $0.82
- P/E Ratio
- BMEA N/A
- LPSN N/A
- Revenue Growth
- BMEA N/A
- LPSN N/A
- 52 Week Low
- BMEA $1.29
- LPSN $0.61
- 52 Week High
- BMEA $13.07
- LPSN $2.08
- Technical
- Relative Strength Index (RSI)
- BMEA 56.62
- LPSN 56.83
- Support Level
- BMEA $1.51
- LPSN $0.93
- Resistance Level
- BMEA $1.86
- LPSN $1.10
- Average True Range (ATR)
- BMEA 0.10
- LPSN 0.12
- MACD
- BMEA 0.03
- LPSN 0.00
- Stochastic Oscillator
- BMEA 91.67
- LPSN 43.10
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.